APO Research
Talk to an analyst

APO RESEARCH · REPORT

Filgrastim and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Filgrastim and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025198 pages

Choose your research edition.

Industry ResearchFilgrastim and Biosimilars Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Filgrastim and Biosimilars Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Filgrastim and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Filgrastim and Biosimilars Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Filgrastim and Biosimilars Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Filgrastim and Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Filgrastim and Biosimilars include Changchun GeneScience Pharmaceutical, CSPC Baike Biopharma, Shanghai Sunway Biotech, Amoytop Biotech, Qilu Pharmaceutical, Kexing Biopharm, Jiangsu Wuzhong Pharmaceutical, North China Pharmaceutical and Hangzhou Jiuyuan Gene Engineering, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Filgrastim and Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Filgrastim and Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Filgrastim and Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Filgrastim and Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Filgrastim and Biosimilars Segment by Company

Changchun GeneScience Pharmaceutical

CSPC Baike Biopharma

Shanghai Sunway Biotech

Amoytop Biotech

Qilu Pharmaceutical

Kexing Biopharm

Jiangsu Wuzhong Pharmaceutical

North China Pharmaceutical

Hangzhou Jiuyuan Gene Engineering

Harbin Pharmaceutical Group

Chengdu Institute of Biological Products

SL Pharm

Teva

Tanvex BioPharma

Sandoz

Pfizer

Kashiv BioSciences

Amgen

Filgrastim and Biosimilars Segment by Type

Single-use Vials

Prefilled Syringes

Filgrastim and Biosimilars Segment by Application

Hospital and Clinic

Pharmacy

Other

Filgrastim and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Filgrastim and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Filgrastim and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Filgrastim and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Filgrastim and Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Filgrastim and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Filgrastim and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Filgrastim and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Filgrastim and Biosimilars Industry Trends Table 2. Filgrastim and Biosimilars Industry Drivers Table 3. Filgrastim and Biosimilars Industry Opportunities and Challenges Table 4. Filgrastim and Biosimilars Industry Restraints Table 5. Global Filgrastim and Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Filgrastim and Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Filgrastim and Biosimilars Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Filgrastim and Biosimilars Sales Market Share by Manufacturers Table 9. Global Filgrastim and Biosimilars Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Filgrastim and Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Filgrastim and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Filgrastim and Biosimilars Manufacturers, Product Type & Application Table 13. Global Filgrastim and Biosimilars Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Filgrastim and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Single-use Vials Table 17. Major Manufacturers of Prefilled Syringes Table 18. Global Filgrastim and Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 20. Global Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 21. Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2026) Table 22. Global Filgrastim and Biosimilars Sales Market Share by Type (2027-2032) Table 23. Global Filgrastim and Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Filgrastim and Biosimilars Revenue by Type (2021-2026) & (K Units) Table 25. Global Filgrastim and Biosimilars Revenue by Type (2027-2032) & (K Units) Table 26. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2026) Table 27. Global Filgrastim and Biosimilars Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital and Clinic Table 29. Major Manufacturers of Pharmacy Table 30. Major Manufacturers of Other Table 31. Global Filgrastim and Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 33. Global Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 34. Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2026) Table 35. Global Filgrastim and Biosimilars Sales Market Share by Application (2027-2032) Table 36. Global Filgrastim and Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Filgrastim and Biosimilars Revenue by Application (2021-2026) & (K Units) Table 38. Global Filgrastim and Biosimilars Revenue by Application (2027-2032) & (K Units) Table 39. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2026) Table 40. Global Filgrastim and Biosimilars Revenue Market Share by Application (2027-2032) Table 41. Global Filgrastim and Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Filgrastim and Biosimilars Sales by Region (2021-2026) & (K Units) Table 43. Global Filgrastim and Biosimilars Sales Market Share by Region (2021-2026) Table 44. Global Filgrastim and Biosimilars Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Filgrastim and Biosimilars Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Filgrastim and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 48. North America Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 49. Europe Filgrastim and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 51. Europe Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Filgrastim and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Filgrastim and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Filgrastim and Biosimilars Sales by Country (2027-2032) & (K Units) Table 58. Global Filgrastim and Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Filgrastim and Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Filgrastim and Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Filgrastim and Biosimilars Revenue Market Share by Region (2021-2026) Table 62. Global Filgrastim and Biosimilars Revenue Market Share by Region (2027-2032) Table 63. Changchun GeneScience Pharmaceutical Company Information Table 64. Changchun GeneScience Pharmaceutical Business Overview Table 65. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 67. Changchun GeneScience Pharmaceutical Recent Development Table 68. CSPC Baike Biopharma Company Information Table 69. CSPC Baike Biopharma Business Overview Table 70. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio Table 72. CSPC Baike Biopharma Recent Development Table 73. Shanghai Sunway Biotech Company Information Table 74. Shanghai Sunway Biotech Business Overview Table 75. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio Table 77. Shanghai Sunway Biotech Recent Development Table 78. Amoytop Biotech Company Information Table 79. Amoytop Biotech Business Overview Table 80. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Amoytop Biotech Filgrastim and Biosimilars Product Portfolio Table 82. Amoytop Biotech Recent Development Table 83. Qilu Pharmaceutical Company Information Table 84. Qilu Pharmaceutical Business Overview Table 85. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 87. Qilu Pharmaceutical Recent Development Table 88. Kexing Biopharm Company Information Table 89. Kexing Biopharm Business Overview Table 90. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Kexing Biopharm Filgrastim and Biosimilars Product Portfolio Table 92. Kexing Biopharm Recent Development Table 93. Jiangsu Wuzhong Pharmaceutical Company Information Table 94. Jiangsu Wuzhong Pharmaceutical Business Overview Table 95. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 97. Jiangsu Wuzhong Pharmaceutical Recent Development Table 98. North China Pharmaceutical Company Information Table 99. North China Pharmaceutical Business Overview Table 100. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 102. North China Pharmaceutical Recent Development Table 103. Hangzhou Jiuyuan Gene Engineering Company Information Table 104. Hangzhou Jiuyuan Gene Engineering Business Overview Table 105. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio Table 107. Hangzhou Jiuyuan Gene Engineering Recent Development Table 108. Harbin Pharmaceutical Group Company Information Table 109. Harbin Pharmaceutical Group Business Overview Table 110. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio Table 112. Harbin Pharmaceutical Group Recent Development Table 113. Chengdu Institute of Biological Products Company Information Table 114. Chengdu Institute of Biological Products Business Overview Table 115. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio Table 117. Chengdu Institute of Biological Products Recent Development Table 118. SL Pharm Company Information Table 119. SL Pharm Business Overview Table 120. SL Pharm Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. SL Pharm Filgrastim and Biosimilars Product Portfolio Table 122. SL Pharm Recent Development Table 123. Teva Company Information Table 124. Teva Business Overview Table 125. Teva Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Teva Filgrastim and Biosimilars Product Portfolio Table 127. Teva Recent Development Table 128. Tanvex BioPharma Company Information Table 129. Tanvex BioPharma Business Overview Table 130. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio Table 132. Tanvex BioPharma Recent Development Table 133. Sandoz Company Information Table 134. Sandoz Business Overview Table 135. Sandoz Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Sandoz Filgrastim and Biosimilars Product Portfolio Table 137. Sandoz Recent Development Table 138. Pfizer Company Information Table 139. Pfizer Business Overview Table 140. Pfizer Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Pfizer Filgrastim and Biosimilars Product Portfolio Table 142. Pfizer Recent Development Table 143. Kashiv BioSciences Company Information Table 144. Kashiv BioSciences Business Overview Table 145. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio Table 147. Kashiv BioSciences Recent Development Table 148. Amgen Company Information Table 149. Amgen Business Overview Table 150. Amgen Filgrastim and Biosimilars Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Amgen Filgrastim and Biosimilars Product Portfolio Table 152. Amgen Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Filgrastim and Biosimilars Distributors List Table 156. Filgrastim and Biosimilars Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Filgrastim and Biosimilars Product Image Figure 2. Global Filgrastim and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Filgrastim and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Filgrastim and Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global Filgrastim and Biosimilars Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Filgrastim and Biosimilars Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Single-use Vials Image Figure 9. Prefilled Syringes Image Figure 10. Global Filgrastim and Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Filgrastim and Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2032) Figure 13. Global Filgrastim and Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Filgrastim and Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2032) Figure 16. Hospital and Clinic Image Figure 17. Pharmacy Image Figure 18. Other Image Figure 19. Global Filgrastim and Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Filgrastim and Biosimilars Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2032) Figure 22. Global Filgrastim and Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Filgrastim and Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2032) Figure 25. North America Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 27. U.S. Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 32. Germany Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 39. China Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Filgrastim and Biosimilars Sales Market Share by Country (2021-2032) Figure 47. Brazil Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Filgrastim and Biosimilars Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Filgrastim and Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Filgrastim and Biosimilars Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 58. North America Filgrastim and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 60. Europe Filgrastim and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Filgrastim and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Filgrastim and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Filgrastim and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Filgrastim and Biosimilars Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Filgrastim and Biosimilars Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Single-use Vials
  • Prefilled Syringes
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Changchun GeneScience Pharmaceutical
  • CSPC Baike Biopharma
  • Shanghai Sunway Biotech
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • Kexing Biopharm
  • Jiangsu Wuzhong Pharmaceutical
  • North China Pharmaceutical
  • Hangzhou Jiuyuan Gene Engineering
  • Harbin Pharmaceutical Group
  • Chengdu Institute of Biological Products
  • SL Pharm
  • Teva
  • Tanvex BioPharma
  • Sandoz
  • Pfizer
  • Kashiv BioSciences
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Filgrastim and Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Filgrastim and Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Filgrastim and Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Filgrastim and Biosimilars Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Filgrastim and Biosimilars Market Dynamics
  1. 2.1 Filgrastim and Biosimilars Industry Trends
  2. 2.2 Filgrastim and Biosimilars Industry Drivers
  3. 2.3 Filgrastim and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Filgrastim and Biosimilars Industry Restraints
3 Filgrastim and Biosimilars Market by Manufacturers
  1. 3.1 Global Filgrastim and Biosimilars Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Filgrastim and Biosimilars Sales by Manufacturers (2021-2026)
  3. 3.3 Global Filgrastim and Biosimilars Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Filgrastim and Biosimilars Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Filgrastim and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Filgrastim and Biosimilars Manufacturers, Product Type & Application
  7. 3.7 Global Filgrastim and Biosimilars Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Filgrastim and Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Filgrastim and Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Filgrastim and Biosimilars Tier 1, Tier 2, and Tier 3
4 Filgrastim and Biosimilars Market by Type
  1. 4.1 Filgrastim and Biosimilars Type Introduction
  2. 4.1.1 Single-use Vials
  3. 4.1.2 Prefilled Syringes
  4. 4.2 Global Filgrastim and Biosimilars Sales by Type
  5. 4.2.1 Global Filgrastim and Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Filgrastim and Biosimilars Sales by Type (2021-2032)
  7. 4.2.3 Global Filgrastim and Biosimilars Sales Market Share by Type (2021-2032)
  8. 4.3 Global Filgrastim and Biosimilars Revenue by Type
  9. 4.3.1 Global Filgrastim and Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Filgrastim and Biosimilars Revenue by Type (2021-2032)
  11. 4.3.3 Global Filgrastim and Biosimilars Revenue Market Share by Type (2021-2032)
5 Filgrastim and Biosimilars Market by Application
  1. 5.1 Filgrastim and Biosimilars Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Filgrastim and Biosimilars Sales by Application
  6. 5.2.1 Global Filgrastim and Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Filgrastim and Biosimilars Sales by Application (2021-2032)
  8. 5.2.3 Global Filgrastim and Biosimilars Sales Market Share by Application (2021-2032)
  9. 5.3 Global Filgrastim and Biosimilars Revenue by Application
  10. 5.3.1 Global Filgrastim and Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Filgrastim and Biosimilars Revenue by Application (2021-2032)
  12. 5.3.3 Global Filgrastim and Biosimilars Revenue Market Share by Application (2021-2032)
6 Global Filgrastim and Biosimilars Sales by Region
  1. 6.1 Global Filgrastim and Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Filgrastim and Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Filgrastim and Biosimilars Sales by Region (2021-2026)
  4. 6.2.2 Global Filgrastim and Biosimilars Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Filgrastim and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Filgrastim and Biosimilars Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Filgrastim and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Filgrastim and Biosimilars Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Filgrastim and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Filgrastim and Biosimilars Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Filgrastim and Biosimilars Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Filgrastim and Biosimilars Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Filgrastim and Biosimilars Revenue by Region
  1. 7.1 Global Filgrastim and Biosimilars Revenue by Region
  2. 7.1.1 Global Filgrastim and Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Filgrastim and Biosimilars Revenue by Region (2021-2026)
  4. 7.1.3 Global Filgrastim and Biosimilars Revenue by Region (2027-2032)
  5. 7.1.4 Global Filgrastim and Biosimilars Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Filgrastim and Biosimilars Revenue (2021-2032)
  8. 7.2.2 North America Filgrastim and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Filgrastim and Biosimilars Revenue (2021-2032)
  11. 7.3.2 Europe Filgrastim and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Filgrastim and Biosimilars Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Filgrastim and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Filgrastim and Biosimilars Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Filgrastim and Biosimilars Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun GeneScience Pharmaceutical
  2. 8.1.1 Changchun GeneScience Pharmaceutical Company Information
  3. 8.1.2 Changchun GeneScience Pharmaceutical Business Overview
  4. 8.1.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  6. 8.1.5 Changchun GeneScience Pharmaceutical Recent Developments
  7. 8.2 CSPC Baike Biopharma
  8. 8.2.1 CSPC Baike Biopharma Company Information
  9. 8.2.2 CSPC Baike Biopharma Business Overview
  10. 8.2.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio
  12. 8.2.5 CSPC Baike Biopharma Recent Developments
  13. 8.3 Shanghai Sunway Biotech
  14. 8.3.1 Shanghai Sunway Biotech Company Information
  15. 8.3.2 Shanghai Sunway Biotech Business Overview
  16. 8.3.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio
  18. 8.3.5 Shanghai Sunway Biotech Recent Developments
  19. 8.4 Amoytop Biotech
  20. 8.4.1 Amoytop Biotech Company Information
  21. 8.4.2 Amoytop Biotech Business Overview
  22. 8.4.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Amoytop Biotech Filgrastim and Biosimilars Product Portfolio
  24. 8.4.5 Amoytop Biotech Recent Developments
  25. 8.5 Qilu Pharmaceutical
  26. 8.5.1 Qilu Pharmaceutical Company Information
  27. 8.5.2 Qilu Pharmaceutical Business Overview
  28. 8.5.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  30. 8.5.5 Qilu Pharmaceutical Recent Developments
  31. 8.6 Kexing Biopharm
  32. 8.6.1 Kexing Biopharm Company Information
  33. 8.6.2 Kexing Biopharm Business Overview
  34. 8.6.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kexing Biopharm Filgrastim and Biosimilars Product Portfolio
  36. 8.6.5 Kexing Biopharm Recent Developments
  37. 8.7 Jiangsu Wuzhong Pharmaceutical
  38. 8.7.1 Jiangsu Wuzhong Pharmaceutical Company Information
  39. 8.7.2 Jiangsu Wuzhong Pharmaceutical Business Overview
  40. 8.7.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  42. 8.7.5 Jiangsu Wuzhong Pharmaceutical Recent Developments
  43. 8.8 North China Pharmaceutical
  44. 8.8.1 North China Pharmaceutical Company Information
  45. 8.8.2 North China Pharmaceutical Business Overview
  46. 8.8.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  48. 8.8.5 North China Pharmaceutical Recent Developments
  49. 8.9 Hangzhou Jiuyuan Gene Engineering
  50. 8.9.1 Hangzhou Jiuyuan Gene Engineering Company Information
  51. 8.9.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  52. 8.9.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio
  54. 8.9.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  55. 8.10 Harbin Pharmaceutical Group
  56. 8.10.1 Harbin Pharmaceutical Group Company Information
  57. 8.10.2 Harbin Pharmaceutical Group Business Overview
  58. 8.10.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio
  60. 8.10.5 Harbin Pharmaceutical Group Recent Developments
  61. 8.11 Chengdu Institute of Biological Products
  62. 8.11.1 Chengdu Institute of Biological Products Company Information
  63. 8.11.2 Chengdu Institute of Biological Products Business Overview
  64. 8.11.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio
  66. 8.11.5 Chengdu Institute of Biological Products Recent Developments
  67. 8.12 SL Pharm
  68. 8.12.1 SL Pharm Company Information
  69. 8.12.2 SL Pharm Business Overview
  70. 8.12.3 SL Pharm Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 SL Pharm Filgrastim and Biosimilars Product Portfolio
  72. 8.12.5 SL Pharm Recent Developments
  73. 8.13 Teva
  74. 8.13.1 Teva Company Information
  75. 8.13.2 Teva Business Overview
  76. 8.13.3 Teva Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Teva Filgrastim and Biosimilars Product Portfolio
  78. 8.13.5 Teva Recent Developments
  79. 8.14 Tanvex BioPharma
  80. 8.14.1 Tanvex BioPharma Company Information
  81. 8.14.2 Tanvex BioPharma Business Overview
  82. 8.14.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio
  84. 8.14.5 Tanvex BioPharma Recent Developments
  85. 8.15 Sandoz
  86. 8.15.1 Sandoz Company Information
  87. 8.15.2 Sandoz Business Overview
  88. 8.15.3 Sandoz Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sandoz Filgrastim and Biosimilars Product Portfolio
  90. 8.15.5 Sandoz Recent Developments
  91. 8.16 Pfizer
  92. 8.16.1 Pfizer Company Information
  93. 8.16.2 Pfizer Business Overview
  94. 8.16.3 Pfizer Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Pfizer Filgrastim and Biosimilars Product Portfolio
  96. 8.16.5 Pfizer Recent Developments
  97. 8.17 Kashiv BioSciences
  98. 8.17.1 Kashiv BioSciences Company Information
  99. 8.17.2 Kashiv BioSciences Business Overview
  100. 8.17.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio
  102. 8.17.5 Kashiv BioSciences Recent Developments
  103. 8.18 Amgen
  104. 8.18.1 Amgen Company Information
  105. 8.18.2 Amgen Business Overview
  106. 8.18.3 Amgen Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Amgen Filgrastim and Biosimilars Product Portfolio
  108. 8.18.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Filgrastim and Biosimilars Value Chain Analysis
  2. 9.1.1 Filgrastim and Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Filgrastim and Biosimilars Production Mode & Process
  6. 9.2 Filgrastim and Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Filgrastim and Biosimilars Distributors
  9. 9.2.3 Filgrastim and Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst